Avital Beig

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
No aliases are listed.
Publication record
31 papers · 1,807 citations · H-index 20

PAPERS

In vitro performance of composition-equivalent PLGA microspheres encapsulating exenatide acetate by solvent evaporation.
20237 citationsauthor #2
Minimizing the initial burst of octreotide acetate based long-acting microspheres by the solvent evaporation method.
20229 citationsauthor #1
Adequate Formulation Approach for Oral Chemotherapy: Etoposide Solubility, Permeability, and Overall Bioavailability from Cosolvent- vs. Vitamin E TPGS-Based Delivery Systems.
202112 citationsauthor #2
Development and characterization of composition-equivalent formulations to the Sandostatin LAR® by the solvent evaporation method
202110 citationsauthor #1
Efficient aqueous remote loading of peptides in poly(lactic-co-glycolic acid)
202136 citationsauthor #6
Physical-chemical characterization of octreotide encapsulated in commercial glucose-star PLGA microspheres.
202033 citationsauthor #1
The solubility, permeability and the dose as key factors in formulation development for oral lipophilic drugs: Maximizing the bioavailability of carbamazepine with cosolvent-based formulation.
202016 citationsauthor #2
Characterization of Attributes and in vitro Performance of Exenatide-loaded PLGA Long-acting Release Microspheres.
202032 citationsauthor #3
Segmental-Dependent Intestinal Drug Permeability: Development and Model Validation of In Silico Predictions Guided by In Vivo Permeability Values.
201917 citationsauthor #6
Solubility, Permeability, and Their Interplay
20183 citationsauthor #1
Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability
201754 citationsauthor #1
Toward Successful Cyclodextrin Based Solubility-Enabling Formulations for Oral Delivery of Lipophilic Drugs: Solubility-Permeability Trade-Off, Biorelevant Dissolution, and the Unstirred Water Layer.
201750 citationsauthor #2
Advantageous Solubility-Permeability Interplay When Using Amorphous Solid Dispersion (ASD) Formulation for the BCS Class IV P-gp Substrate Rifaximin: Simultaneous Increase of Both the Solubility and the Permeability
20176 citationsauthor #1
Striking the Optimal Solubility-Permeability Balance in Oral Formulation Development for Lipophilic Drugs: Maximizing Carbamazepine Blood Levels.
201736 citationsauthor #1
Concomitant solubility‐permeability increase: Vitamin E TPGS vs. amorphous solid dispersion as oral delivery systems for etoposide
201743 citationsauthor #1
The solubility-permeability interplay and oral drug formulation design: Two heads are better than one.
2016169 citationsauthor #2
Hydrotropic Solubilization of Lipophilic Drugs for Oral Delivery: The Effects of Urea and Nicotinamide on Carbamazepine Solubility–Permeability Interplay
201656 citationsauthor #1
Segmental-dependent permeability throughout the small intestine following oral drug administration: Single-pass vs. Doluisio approach to in-situ rat perfusion.
201643 citationsauthor #3
The use of captisol (SBE7-β-CD) in oral solubility-enabling formulations: Comparison to HPβCD and the solubility-permeability interplay.
201560 citationsauthor #1
Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay.
201573 citationsauthor #1
In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluisio experimental approaches.
201564 citationsauthor #4
Quantification of carbamazepine and its 10,11-epoxide metabolite in rat plasma by UPLC-UV and application to pharmacokinetic study.
201415 citationsauthor #1
The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off.
201356 citationsauthor #1
Correction: Oral Delivery of Lipophilic Drugs: The Tradeoff between Solubility Increase and Permeability Decrease When Using Cyclodextrin-Based Formulations
201316 citationsauthor #1
Oral Delivery of Lipophilic Drugs: The Tradeoff between Solubility Increase and Permeability Decrease When Using Cyclodextrin-Based Formulations
2013127 citationsauthor #1
Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption.
2012102 citationsauthor #1
A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability.
2012241 citationsauthor #2
The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
2012130 citationsauthor #2
The Twofold Advantage of the Amorphous Form as an Oral Drug Delivery Practice for Lipophilic Compounds: Increased Apparent Solubility and Drug Flux Through the Intestinal Membrane
201283 citationsauthor #2
Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidino functionality
201114 citationsauthor #3
The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation.
2011194 citationsauthor #2

TIMELINE

2011 208 citations

2012 556 citations

2013 199 citations

2014 15 citations

2015 197 citations

2016 268 citations

2017 189 citations

2018 3 citations

2019 17 citations

2020 81 citations

2021 58 citations

2022 9 citations

2023 7 citations

Avital Beig

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT